Leslie G. Ford

24.3k total citations · 4 hit papers
74 papers, 13.2k citations indexed

About

Leslie G. Ford is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Leslie G. Ford has authored 74 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 27 papers in Genetics and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Leslie G. Ford's work include Cancer Risks and Factors (21 papers), Estrogen and related hormone effects (18 papers) and Global Cancer Incidence and Screening (16 papers). Leslie G. Ford is often cited by papers focused on Cancer Risks and Factors (21 papers), Estrogen and related hormone effects (18 papers) and Global Cancer Incidence and Screening (16 papers). Leslie G. Ford collaborates with scholars based in United States, Australia and Italy. Leslie G. Ford's co-authors include D. Lawrence Wickerham, Ian M. Thompson, Joseph P. Costantino, Walter M. Cronin, Norman Wolmark, André Robidoux, James N. Atkins, Phyllis J. Goodman, M. Scott Lucia and Charles A. Coltman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Leslie G. Ford

73 papers receiving 12.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1998 4.0k citations Joseph P. Costantino, D. Lawrence Wickerham et al. profile →
The Influence of Finasteride on the Development of Prostate Cancer

2003 1.7k citations Ian M. Thompson, Phyllis J. Goodman et al. New England Journal of Medicine profile →
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

2004 1.7k citations Ian M. Thompson, Phyllis J. Goodman et al. New England Journal of Medicine profile →
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

2005 937 citations Joseph P. Costantino, D. Lawrence Wickerham et al. profile →

Peers

Leslie G. Ford

GENET

ONCOL

PRM

John Forbes United Kingdom

Vered Stearns United States

Victor G. Vogel United States

James N. Atkins United States

Patrick Neven Belgium

Paul E. Goss United States

Claudine Isaacs United States

Christopher I. Li United States

Pamela J. Goodwin Canada

Henk‐Jan Guchelaar Netherlands

John Forbes United Kingdom

Leslie G. Ford

5.9k ×1.2

GENET

8.2k ×1.9

ONCOL

3.2k ×0.9

PRM

6.7k ×1.9

2.1k ×0.8

Citations per year, relative to Leslie G. Ford Leslie G. Ford (= 1×) peers John Forbes

Countries citing papers authored by Leslie G. Ford

Since Specialization

Citations

This map shows the geographic impact of Leslie G. Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leslie G. Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leslie G. Ford more than expected).

Fields of papers citing papers by Leslie G. Ford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leslie G. Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leslie G. Ford. The network helps show where Leslie G. Ford may publish in the future.

Co-authorship network of co-authors of Leslie G. Ford

This figure shows the co-authorship network connecting the top 25 collaborators of Leslie G. Ford. A scholar is included among the top collaborators of Leslie G. Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leslie G. Ford. Leslie G. Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thảo, Lê Thị Phương, Tri‐Long Nguyen, Sean Byars, et al.. (2025). Low-Dose Aspirin for Individualized Cancer Prevention in Older Adults. JAMA Oncology. 11(11). 1348–1348.

Heckman‐Stoddard, Brandy M., Jill P. Crandall, Sharon L. Edelstein, et al.. (2025). Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program. Cancer Prevention Research. 18(7). 401–411. 3 indexed citations

Warner, Erica T., Galina Polekhina, Peter Gibbs, et al.. (2024). Cardiovascular disease and stroke following cancer and cancer treatment in older adults. Cancer. 130(23). 4138–4148. 2 indexed citations

Eickhoff, Jens C., Guanhua Chen, Vikrant V. Sahasrabuddhe, et al.. (2023). A Systematic Review and Pooled Analysis of Hypothesized versus Observed Effect Sizes in Early Phase Cancer Prevention Clinical Trials. Cancer Prevention Research. 16(8). 471–478. 1 indexed citations

Samimi, Goli, Brandy M. Heckman‐Stoddard, Christine Holmberg, et al.. (2020). Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians. Cancer Prevention Research. 14(2). 205–214. 8 indexed citations

Zell, Jason A., Christine E. McLaren, Timothy R. Morgan, et al.. (2019). A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index. Cancer Prevention Research. 13(2). 203–212. 23 indexed citations

Crew, Katherine D., Garnet L. Anderson, Dawn L. Hershman, et al.. (2019). Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prevention Research. 12(7). 481–490. 16 indexed citations

Gandini, Sara, Matteo Puntoni, Brandy M. Heckman‐Stoddard, et al.. (2014). Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders. Cancer Prevention Research. 7(9). 867–885. 340 indexed citations

Thompson, Ian M., Phyllis J. Goodman, Catherine M. Tangen, et al.. (2013). Long-Term Survival of Participants in the Prostate Cancer Prevention Trial. New England Journal of Medicine. 369(7). 603–610. 181 indexed citations

10.

Jordan, V. Craig & Leslie G. Ford. (2011). Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A “New” Biology of Estrogen-induced Apoptosis. Cancer Prevention Research. 4(5). 633–637. 46 indexed citations

11.

Runowicz, Carolyn D., Joseph P. Costantino, D. Lawrence Wickerham, et al.. (2011). Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). American Journal of Obstetrics and Gynecology. 205(6). 535.e1–535.e5. 37 indexed citations

12.

Vogel, Victor G., Joseph P. Costantino, D. Lawrence Wickerham, et al.. (2010). Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research. 3(6). 696–706. 438 indexed citations

13.

Pinsky, Paul F., Howard L. Parnes, & Leslie G. Ford. (2008). Estimating Rates of True High-Grade Disease in the Prostate Cancer Prevention Trial. Cancer Prevention Research. 1(3). 182–186. 56 indexed citations

14.

Lucia, M. Scott, Amy K. Darke, Phyllis J. Goodman, et al.. (2008). Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention. Cancer Prevention Research. 1(3). 167–173. 72 indexed citations

15.

Wickerham, D. Lawrence, Joseph P. Costantino, Victor G. Vogel, et al.. (2008). The Use of Tamoxifen and Raloxifene for the Prevention of Breast Cancer. Recent results in cancer research. 181. 113–119. 29 indexed citations

16.

Unger, Joseph M., Ian M. Thompson, Michael LeBlanc, et al.. (2005). Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer. 103(7). 1375–1380. 26 indexed citations

17.

Thompson, Ian M., Phyllis J. Goodman, Catherine M. Tangen, et al.. (2003). The Influence of Finasteride on the Development of Prostate Cancer. New England Journal of Medicine. 349(3). 215–224. 1749 indexed citations breakdown →

18.

Dunn, Barbara K., Worta McCaskill‐Stevens, & Leslie G. Ford. (2000). Breast cancer prevention. European Journal of Cancer. 36. 53–54. 6 indexed citations

19.

Johnson, Karen A., Leslie G. Ford, Barnett S. Kramer, & Peter Greenwald. (1994). Overview of U.S. National Cancer Institute (USNCI) Chemoprevention Research. Acta Oncologica. 33(1). 5–11. 2 indexed citations

20.

Feigl, Polly, et al.. (1988). Studying patterns of cancer care: how useful is the medical record?. American Journal of Public Health. 78(5). 526–533. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact